NeoTX Hosting Key Opinion Leader Webinar on Overcoming Check Point Inhibitor Resistance
07 juil. 2021 16h01 HE
|
NeoTX
REHOVOT, Israel, July 07, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it will host a key opinion leader (KOL) webinar on...
NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate
19 avr. 2021 02h30 HE
|
NeoTX
REHOVOT, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology company, announced today that it received clearance from the U.S. Food and Drug...
NeoTX to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
03 août 2020 08h00 HE
|
NeoTX
REHOVOT, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop...
NeoTX Closes $45 Million Series C Financing
19 févr. 2020 03h00 HE
|
NeoTX
REHOVOT, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop...
NeoTX Therapeutics to Present at the Society for Immunotherapy of Cancer’s 34th Annual Meeting
04 nov. 2019 08h00 HE
|
NeoTX
REHOVOT, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- NeoTX Therapeutics, Ltd. today announced a presentation on the company’s lead candidate from its Selective T cell Redirection (STR) platform,...
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
28 oct. 2019 03h30 HE
|
NeoTX
Dose-escalation study to determine maximum tolerated dose ahead of Phase 2 cohort expansion study Milestone marks initiation of studies in the NeoTX-AstraZeneca collaboration to study Nap in...